Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma

February 2011

Journal of Cancer Research and Clinical Oncology 2011, 137:287.


This study reports on the first clinical trial with perillyl alcohol given via inhalation through the nose (intranasal). It was performed in Brazil and included 89 patients with glioblastoma, the most aggressive brain cancer type, where standard treatment had failed and patients had become unresponsive to standard care. Intranasal administration of perillyl alcohol resulted in increased overall survival of patients, and the side effects of this type of treatment were almost non-existent, even in patients treated for over 4 years.

Comments are closed.